Asceneuron SA
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 2 to 9, 2027 · next Jan 2
- 1 fee due Feb 22, 2027The maintenance fee for Spiro compounds as glycosidase inhibitors (US 11,731,972) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Tetrahydro-benzoazepine glycosidase inhibitors (US 11,795,165) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Glycosidase inhibitors (US 10,556,902) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,505,769 | Tetraaza-cyclopenta[a]indenyl derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 10,336,775 | Glycosidase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,046,712 | Glycosidase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 12,187,741 | Glycosidase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,344,021 | Process for the separation of enantiomers of piperazine derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 10,556,902 | Glycosidase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,696,668 | Acid addition salts of piperazine derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 11,261,183 | Sulfoximine Glycosidase Inhibitors In force · High confidence | In force | High confidence | |
| US 11,591,327 | Acid addition salts of piperazine derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 12,398,130 | Acid addition salts of piperazine derivatives In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 17: 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded